Floatz logo

Recombinant Human Thrombopoietin

Immune Thrombocytopenia

Yin Jieprotein_peptidePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Immune Thrombocytopenia cohort.

Asset / SponsorPhaseRating
Herombopag
Yin Jie
Phase 3B
IMMUNOGLOBULIN G1-LAMBDA2, ANTI-(SEVERE ACUTE RESPIRATORY SYNDROME (HUMAN) CORONAVIRUS 2 (SARS-COV-2) SPIKE (S) GLYCOPROTEIN, RECEPTOR BINDING DOMAIN (RBD)), HOMO SAPIENS MONOCLONAL ANTIBOD
Imperial College Healthcare NHS Trust
Phase 2CCC
OGALVIBART
Imperial College Healthcare NHS Trust
Phase 2CCC
her2bbζ/cd19t+ t cells
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Early Phase 1C
Erythropoietin Human Recombinant
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
D
Fecal Microbiome
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
D
Luspatercept
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
D

Same molecule, other indications

Recombinant Human Thrombopoietin is also rated in:

thrombocytopeniaDormant
BBB
Indicative ·
78 / 100
View asset →
chemotherapy-induced toxicityDormant
B
Indicative ·
60 / 100
View asset →
colorectal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →